Medidata and Cogstate have formed a partnership aimed at transforming clinical trials and outcomes measurement for central nervous system (CNS) diseases. The collaboration focuses on neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders.
The partnership will deliver an improved experience supported by Medidata's electronic clinical outcome assessment (eCOA), which is designed to accelerate trial initiation and optimize rater experiences. This includes a streamlined rater journey via a single mobile device app and a suite of data quality assurance solutions for CNS assessments.
Medidata CEO Anthony Costello stated that the joint effort leverages Medidata's expertise in eCOA, AI, and sensors to enable the highest endpoint data quality standard. The goal is to simplify CNS trial setup and run automated checks on patient assessment transcripts to minimize study team burden and mitigate potential errors.
Cogstate CEO Brad O’Connor emphasized that the strategic combination of science and technology will deliver unique data quality innovations for more informed clinical trial decision-making and better patient outcomes.
The collaboration integrates Medidata’s platform with Cogstate’s validated digital cognitive assessments, expert rater training, and monitoring solutions. This is expected to deliver higher quality data collection with increased efficiency and accuracy.
Enhanced Data Capture
By leveraging the Medidata App with Medidata Rave EDC and Medidata eCOA features designed for CNS trials, raters will gain greater precision in managing their studies, initiating patient site visits, and completing intricate CNS assessments on the site tablet. The app offers upgraded data capture, including enhanced controls and navigation, flexible annotation options, and embedded audio recording with smart transcription to allow for greater scoring accuracy and reduced rater burden.
Leaders from Medidata and Cogstate will present further details about the partnership and advances in CNS clinical trial optimization at Medidata NEXT New York.
